<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04096001</url>
  </required_header>
  <id_info>
    <org_study_id>1R44DA048712-01</org_study_id>
    <nct_id>NCT04096001</nct_id>
  </id_info>
  <brief_title>Woebot for Substance Use Disorders</brief_title>
  <official_title>RCT of Woebot for Substance Use Disorders Phase 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Woebot Labs, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Woebot Labs, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 of this study aims to develop a digitally-delivered substance use disorder program&#xD;
      through the Woebot app-based platform (W-SUDs) and evaluate the effectiveness of, patient&#xD;
      satisfaction with and the acceptability of W-SUDs as a substance use management tool.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 26, 2020</start_date>
  <completion_date type="Actual">August 31, 2020</completion_date>
  <primary_completion_date type="Actual">August 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Alcohol Use Disorders Identification Test-Consumption (AUDIT-C)</measure>
    <time_frame>Change from Baseline to Post-treatment at 12 weeks</time_frame>
    <description>The AUDIT-C is a widely used 3-item self-report screen for hazardous or harmful alcohol consumption that is based off of the 10-item original AUDIT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Drug Abuse Screening Test 10 (DAST-10)</measure>
    <time_frame>Change from Baseline to Post-treatment at 12 weeks</time_frame>
    <description>The DAST-10 is a brief, 10-item self-report assesses consequences related to drug abuse, excluding alcohol and tobacco.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Client Satisfaction Questionnaire (CSQ-8)</measure>
    <time_frame>Post-treatment at 12 weeks</time_frame>
    <description>The CSQ-8 is an 8-item self-report scale measuring satisfaction with treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usage Rating Profile Intervention Acceptability Subscale (URPI-usability subscale)</measure>
    <time_frame>Post-treatment at 12 weeks</time_frame>
    <description>URPI-Acceptability Subscale is 6-item subscale from the URP Intervention Revised (URP-IR) scale. The URPI-Acceptability inquires about intervention acceptability. Responses range from 1= &quot;slightly disagree&quot; to 6=&quot;strongly agree&quot;. Scores are averages, with greater scores indicating greater intervention acceptability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usage Rating Profile Intervention Feasibility Subscale (URPI-feasibility subscale)</measure>
    <time_frame>Post-treatment at 12 weeks</time_frame>
    <description>URPI-Feasibility Subscale is 6-item subscale from the URP Intervention Revised (URP-IR) scale. The URPI-Feasibility inquires about factors that impact treatment usage (i.e., intervention quality). Responses range from 1= &quot;slightly disagree&quot; to 6=&quot;strongly agree&quot;. Scores are averages, with greater scores indicating greater intervention feasibility.</description>
  </secondary_outcome>
  <enrollment type="Actual">101</enrollment>
  <condition>Substance Use Disorders</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Woebot-SUDs (W-SUDs)</intervention_name>
    <description>Woebot-SUDs (W-SUDS), an artificially intelligence-powered conversational agent on a smartphone app, eliminates most current SUDs treatment barriers while simultaneously leveraging technology to enhance user experience and engagement. W-SUDs expands and refines existing SUDs treatments by adapting skills from cognitive behavioral therapy, motivational interviewing, and dialectical behavior therapy.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All genders&#xD;
&#xD;
          -  18-65 years&#xD;
&#xD;
          -  Must have access to a smartphone and able to download the W-SUDs app&#xD;
&#xD;
          -  Committed to engage with app and complete assessments&#xD;
&#xD;
          -  Be willing to provide email address (to distribute incentives)&#xD;
&#xD;
          -  Be literate in English (as W-SUDs conversational and video materials will be in&#xD;
             English)&#xD;
&#xD;
          -  Endorse a substance use concern according to the DAST-10 and/or AUDIT-C scale cutoffs&#xD;
             for problematic use&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy (as W-SUDs will not be specifically developed to address the unique needs of&#xD;
             this population)&#xD;
&#xD;
          -  Suicide attempt or within the past year&#xD;
&#xD;
          -  Drug or alcohol overdose within the past year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Woebot Labs Inc</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 16, 2019</study_first_submitted>
  <study_first_submitted_qc>September 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2019</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 28, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT04096001/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

